Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) Equity Ratio (2023 - 2025)

Zenas BioPharma has reported Equity Ratio over the past 3 years, most recently at 0.63 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.63 for Q4 2025, down 25.27% from a year ago — trailing twelve months through Dec 2025 was 0.63 (down 25.27% YoY), and the annual figure for FY2025 was 0.63, down 25.27%.
  • Equity Ratio for Q4 2025 was 0.63 at Zenas BioPharma, up from 0.61 in the prior quarter.
  • Over the last five years, Equity Ratio for ZBIO hit a ceiling of 0.89 in Q3 2024 and a floor of 3.31 in Q4 2023.
  • Median Equity Ratio over the past 3 years was 0.82 (2025), compared with a mean of 0.19.
  • Biggest five-year swings in Equity Ratio: surged 125.51% in 2024 and later plummeted 31.53% in 2025.
  • Zenas BioPharma's Equity Ratio stood at 3.31 in 2023, then surged by 125.51% to 0.84 in 2024, then fell by 25.27% to 0.63 in 2025.
  • The last three reported values for Equity Ratio were 0.63 (Q4 2025), 0.61 (Q3 2025), and 0.82 (Q2 2025) per Business Quant data.